{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:14:21Z","timestamp":1780481661937,"version":"3.54.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Cancer Prevention & Research Institute of Texas Early Clinical Investigator","award":["RP220544"],"award-info":[{"award-number":["RP220544"]}]},{"name":"University of Texas MD Anderson Physician-Scientist Program"},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Texas MD Anderson Institutional Research"},{"name":"MD Anderson Sarcoma SPORE Career Enhancement Program"},{"DOI":"10.13039\/100009272","name":"Chordoma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Neuroscience Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chordoma is a midline neoplasm accounting for approximately 20% of primary spinal tumors. Due to chordoma\u2019s locally aggressive nature, patients experience high rates of disease progression and have limited treatment options, highlighting an unmet clinical need. This underscores the importance of exploring novel therapeutic strategies. Oncolytic viral (OV) therapy uses genetically modified viruses to selectively replicate in tumor cells, mediate tumor cell lysis, and initiate a pro-inflammatory response within the infected tumor microenvironment (TME). The aim of the study was to evaluate the anti-chordoma effect of the replicating oncolytic adenovirus Delta-24-RGD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The efficacy of Delta-24-RGD was assessed using in vitro approaches, ex vivo bone scaffolds, and in vivo murine models. Additionally, we explored the underlying mechanism of OV cytotoxicity, immunogenic cell death (ICD), brachyury modulation, and reshaping of the TME towards a pro-inflammatory state.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Delta-24-RGD achieved viral infectivity, oncolysis, and ICD across multiple human chordoma cell lines and ex vivo bone scaffold models. In vivo murine xenograft models of human CH22 and U-CH1 chordoma treated with Delta-24-RGD resulted in tumor volume reduction, enhanced overall survival, and microenvironmental transcriptional modulation. Analyzing a human chordoma tissue microarray, the immunosuppressive macrophage marker CD163 was associated with shortened recurrence-free survival. Using macrophage\/chordoma co-culture, OV infection achieved a reduction in macrophage CD163 expression and a concomitant pro-inflammatory macrophage polarization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The immunosuppressive chordoma TME is associated with clinical outcomes and our data suggests OV infection reverses this deleterious immunosuppressive profile. These studies provide a framework for future clinical implementation among chordoma patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag045","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T12:51:30Z","timestamp":1772283090000},"page":"1458-1473","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic adenoviral infection of chordoma achieves treatment efficacy associated with immunologic response and tumor microenvironmental alteration"],"prefix":"10.1093","volume":"28","author":[{"given":"Xizi","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ledbetter","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Wei","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Gumin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G","family":"Gillard","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Ho","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"Ingram","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir","family":"Akdemir","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P","family":"Conley","sequence":"additional","affiliation":[{"name":"Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6395-4499","authenticated-orcid":false,"given":"Alexander J","family":"Lazar","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaan","family":"Raza","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"North","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Tatsui","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3747-873X","authenticated-orcid":false,"given":"Frederick F","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wein-Lien","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence D","family":"Rhines","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-2133","authenticated-orcid":false,"given":"Candelaria","family":"Gomez-Manzano","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6941-2335","authenticated-orcid":false,"given":"Juan","family":"Fueyo","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-6532","authenticated-orcid":false,"given":"Christopher","family":"Alvarez-Breckenridge","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2026060305365025600_noag045-B1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11060-020-03511-x","article-title":"Descriptive epidemiology of chordomas in the United States","volume":"148","author":"Das","year":"2020","journal-title":"J Neurooncol"},{"key":"2026060305365025600_noag045-B2","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/annonc\/mdx054","article-title":"Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group","volume":"28","author":"Stacchiotti","year":"2017","journal-title":"Ann Oncol"},{"key":"2026060305365025600_noag045-B3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejca.2017.06.038","article-title":"Medical treatment of advanced chordomas","volume":"83","author":"Colia","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026060305365025600_noag045-B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2023-008138","article-title":"Multimodal profiling of chordoma immunity reveals distinct immune contextures","volume":"12","author":"van Oost","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026060305365025600_noag045-B5","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1007\/s00262-022-03152-1","article-title":"Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas","volume":"71","author":"Duan","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2026060305365025600_noag045-B6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","article-title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSe Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","volume":"24","author":"Blay","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026060305365025600_noag045-B7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/CJI.0000000000000431","article-title":"Immune checkpoint inhibitors have clinical activity in patients with recurrent chordoma","volume":"45","author":"Bishop","year":"2022","journal-title":"J Immunother"},{"key":"2026060305365025600_noag045-B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-003238","volume":"9","author":"DeMaria PJ, Lee-Wisdom K, Donahue RN, et al. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026060305365025600_noag045-B9","doi-asserted-by":"publisher","first-page":"659662","DOI":"10.3389\/fonc.2021.659662","article-title":"B7-H3 as a target for CAR-T cell therapy in skull base chordoma","volume":"11","author":"Long","year":"2021","journal-title":"Front Oncol"},{"key":"2026060305365025600_noag045-B10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world\u2019s first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2026060305365025600_noag045-B11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/imt.15.35","article-title":"Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Immunotherapy"},{"key":"2026060305365025600_noag045-B12","author":"Daiichi Sankyo Co. Ltd","year":"2021"},{"key":"2026060305365025600_noag045-B13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2026060305365025600_noag045-B14","first-page":"120","article-title":"A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency","volume":"7","author":"Suzuki","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2026060305365025600_noag045-B15","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026060305365025600_noag045-B16","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"Gallego Perez-Larraya","year":"2022","journal-title":"N Engl J Med"},{"key":"2026060305365025600_noag045-B17","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/jbmr.2253","article-title":"The oncolytic adenovirus Delta24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity","volume":"29","author":"Martinez-Velez","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2026060305365025600_noag045-B18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1158\/1535-7163.MCT-21-0565","article-title":"Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune memory","volume":"21","author":"Martinez-Velez","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2026060305365025600_noag045-B19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41467-021-21026-5","article-title":"Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival","volume":"12","author":"Bai","year":"2021","journal-title":"Nat Commun"},{"key":"2026060305365025600_noag045-B20","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1158\/0008-5472.CAN-14-3270","article-title":"Preclinical characterization of novel chordoma cell systems and their targeting by pharmocological inhibitors of the CDK4\/6 cell-cycle pathway","volume":"75","author":"von Witzleben","year":"2015","journal-title":"Cancer Res"},{"key":"2026060305365025600_noag045-B21","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Martinez-Velez","year":"2019","journal-title":"Nat Commun"},{"key":"2026060305365025600_noag045-B22","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1158\/1078-0432.CCR-19-0405","article-title":"Localized treatment with oncolytic adenovirus Delta-24-RGDOX induces systemic immunity against disseminated subcutaneous and intracranial melanomas","volume":"25","author":"Jiang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026060305365025600_noag045-B23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","article-title":"HISAT: a fast spliced aligner with low memory requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat Methods"},{"key":"2026060305365025600_noag045-B24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nbt.3122","article-title":"StringTie enables improved reconstruction of a transcriptome from RNA-seq reads","volume":"33","author":"Pertea","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2026060305365025600_noag045-B25","doi-asserted-by":"publisher","first-page":"i172","DOI":"10.1093\/bioinformatics\/bts236","article-title":"Xenome\u2014a tool for classifying reads from xenograft samples","volume":"28","author":"Conway","year":"2012","journal-title":"Bioinformatics"},{"key":"2026060305365025600_noag045-B26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1535-7163.MCT-23-0796","article-title":"Multiomic-based molecular landscape of FaDu xenograft tumors in mice after a combinatorial treatment with radiation and an HSP90 inhibitor identifies adaptation-induced targets of resistance and therapeutic intervention","volume":"23","author":"Bylicky","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"2026060305365025600_noag045-B27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/sj.bjc.6604130","article-title":"Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation","volume":"98","author":"Hallor","year":"2008","journal-title":"Br J Cancer"},{"key":"2026060305365025600_noag045-B28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"2026060305365025600_noag045-B29","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1158\/1078-0432.CCR-20-3313","article-title":"Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT\/RT and CNS-PNET","volume":"27","author":"Garcia-Moure","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026060305365025600_noag045-B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.176962","article-title":"Tumor treating fields suppress tumor cell growth and neurologic decline in models of spinal metastases","volume":"9","author":"Ledbetter","year":"2024","journal-title":"JCI Insight"},{"key":"2026060305365025600_noag045-B31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"2026060305365025600_noag045-B32","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"key":"2026060305365025600_noag045-B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2023-006808","article-title":"Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression","volume":"11","author":"Xu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026060305365025600_noag045-B34","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.2217\/fon-2022-0481","article-title":"BETA PRIME: phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors","volume":"18","author":"Kesari","year":"2022","journal-title":"Future Oncol"},{"key":"2026060305365025600_noag045-B35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41417-023-00720-0","article-title":"BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors","volume":"31","author":"Conley","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"2026060305365025600_noag045-B36","doi-asserted-by":"publisher","first-page":"e97407","DOI":"10.1371\/journal.pone.0097407","article-title":"Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model","volume":"9","author":"Jiang","year":"2014","journal-title":"PLoS One"},{"key":"2026060305365025600_noag045-B37","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2767-9764.CRC-23-0054","article-title":"Adjuvant therapy with oncolytic adenovirus delta-24-RGDOX after intratumoral adoptive T-cell therapy promotes antigen spread to sustain systemic antitumor immunity","volume":"3","author":"Jiang","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026060305365025600_noag045-B38","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1158\/0008-5472.CAN-20-1387","article-title":"Inhibition of histone H3K27 demethylases inactivates brachyury (TBXT) and promotes chordoma cell death","volume":"80","author":"Cottone","year":"2020","journal-title":"Cancer Res"},{"key":"2026060305365025600_noag045-B39","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41591-018-0312-3","article-title":"Small-molecule targeting of brachyury transcription factor addiction in chordoma","volume":"25","author":"Sharifnia","year":"2019","journal-title":"Nat Med"},{"key":"2026060305365025600_noag045-B40","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2026060305365025600_noag045-B41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40425-019-0505-4","article-title":"Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager","volume":"7","author":"de Sostoa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026060305365025600_noag045-B42","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/0008-5472.CAN-05-2242","article-title":"Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector","volume":"66","author":"McKee","year":"2006","journal-title":"Cancer Res"},{"key":"2026060305365025600_noag045-B43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026060305365025600_noag045-B44","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s43018-022-00448-0","article-title":"Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity","volume":"3","author":"Tian","year":"2022","journal-title":"Nat Cancer"},{"key":"2026060305365025600_noag045-B45","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/cgt.2011.46","article-title":"Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity","volume":"18","author":"Fu","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"2026060305365025600_noag045-B46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41467-023-44576-2","article-title":"Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma","volume":"15","author":"Dai","year":"2024","journal-title":"Nat Commun"},{"key":"2026060305365025600_noag045-B47","doi-asserted-by":"publisher","first-page":"1012058","DOI":"10.3389\/fonc.2022.1012058","article-title":"Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies","volume":"12","author":"Lopez","year":"2022","journal-title":"Front Oncol"},{"key":"2026060305365025600_noag045-B48","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s44321-025-00225-3","article-title":"Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus","volume":"17","author":"Wang","year":"2025","journal-title":"EMBO Mol Med"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag045\/67273409\/noag045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag045\/67273409\/noag045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag045\/67273409\/noag045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:37:00Z","timestamp":1780479420000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/6\/1458\/8510737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,22]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag045","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,22]]}}}